Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Change in Account Payables (2016 - 2019)

Ultragenyx Pharmaceutical has reported Change in Account Payables over the past 4 years, most recently at $3.9 million for Q3 2019.

  • Quarterly Change in Account Payables rose 298.58% to $3.9 million in Q3 2019 from the year-ago period, while the trailing twelve-month figure was $4.2 million through Sep 2019, up 517.67% year-over-year, with the annual reading at $3.4 million for FY2018, 2.52% down from the prior year.
  • Change in Account Payables was $3.9 million for Q3 2019 at Ultragenyx Pharmaceutical, up from -$3.5 million in the prior quarter.
  • Over five years, Change in Account Payables peaked at $4.0 million in Q4 2018 and troughed at -$3.5 million in Q2 2019.
  • The 4-year median for Change in Account Payables is $187000.0 (2016), against an average of $639933.3.
  • The largest YoY upside for Change in Account Payables was 1698.93% in 2017 against a maximum downside of 343.26% in 2017.
  • A 4-year view of Change in Account Payables shows it stood at -$1.3 million in 2016, then soared by 68.66% to -$420000.0 in 2017, then soared by 1044.05% to $4.0 million in 2018, then dropped by 1.39% to $3.9 million in 2019.
  • Per Business Quant, the three most recent readings for RARE's Change in Account Payables are $3.9 million (Q3 2019), -$3.5 million (Q2 2019), and -$151000.0 (Q1 2019).